Link Biologics strengthens IP position for Link_TSG6 with US patent Notice of Allowance and University of Manchester IP assignment

/in

Secures long‑term ownership and protection of Link_TSG6, strengthening its global IP position in key markets De‑risks development and enhances long‑term value, supporting advancement towards clinical development London, UK – 6 May 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies that have a unique combination of anti-inflammatory, tissue-protective and […]

Read more

Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy

/in

AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune system Data to be presented at ASGCT 2026 show when used as a monotherapy, AT-108 doubled median survival When used in combination with immune checkpoint blockade (ICB), AT-108 demonstrated strong anti-tumor activity, including significantly extending survival and achieving […]

Read more

Poolbeg Pharma plc – Results for the year ended 31 December 2025

/in

28 April 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its audited results for the year ended 31 December 2025. Read more…

Read more

Oncoinvent ASA: Annual Report for 2025

/in

Oslo, Norway, 22 April 2026 – Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced the publication of the Annual Report for 2025. Read more…

Read more

New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources

/in

The Novo Nordisk Foundation Challenge Programme supports development of new knowledge to help tackle major societal challenges within human and planetary health. With total funding up to €80 million, four new themes are now open for applications from interdisciplinary research teams across Europe. From the way we diagnose disease to how we produce chemicals and […]

Read more
© Optimum Strategic Communications.